Paller, A S <br/><br/>
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).  [electronic resource] 

 -  The British journal of dermatology  08 2020 
 - 231-241 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1365-2133 
<br/><br/><label>Standard No.: </label>10.1111/bjd.19147  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal, Humanized<br/>Child<br/>Dermatologic Agents--adverse effects<br/>Double-Blind Method<br/>Etanercept<br/>Humans<br/>Psoriasis--drug therapy<br/>Quality of Life<br/>Severity of Illness Index<br/>Treatment Outcome